Adams Respiratory Therapeutics Inc
Adams Respiratory Therapeutics — Deutsche Bank 2006 Small Cap Growth Conference
33 slides from Adams Respiratory Therapeutics's conference presentation, Feb 16, 2006

Slide 1: Deutsche Bank 2006 Small Cap Growth Conference
Deutsche Bank 2006 Small Cap Growth Conference February 16, 2006

Slide 2: Safe Harbor
Safe Harbor This presentation contains certain "forward-looking" statements. These statements are based on the current estimates and assumptions of the management of Adams Respiratory Therapeutics, Inc. (or "Adams") as of the date of this presentation and are naturally subject to uncertainty and cha

Slide 3: Adams is a Specialty Pharmaceutical Company
Adams is a Specialty Pharmaceutical Company Focused on: Late-stage development and commercialization OTC and prescription pharmaceuticals for the treatment of respiratory disorders

Slide 4: Investment Highlights
Mucinex(r) is the only FDA-approved extended-release line of expectorants in the U.S. A rapidly growing respiratory portfolio Mucinex(r), Mucinex(r) DM and now, Mucinex(r) D Franchise holds the #1, 2, and 3 SKU's on an "all outlets" basis* Humibid(r) maximum-strength expectorant to be launched March

Slide 5: Solid Financial Performance
12-Months Ended 6-Months Ended June 30 December 31 Solid Financial Performance (in millions) Revenues Pretax Income +126% Pretax Income +149% YoY Growth 161% YoY Growth 78% $110.3 $62.0 $160.2 $61.3 $0.0 $50.0 $100.0 $150.0 $200.0 2004 2005 2004 2005

Slide 6: Operational Achievements - FY 2006 (YTD)
Entered '05/'06 cough/cold season with dramatically improved retail presence Tremendous off-shelf display support and major distribution gains Launched Mrs. Mucus(tm) advertising campaign (Oct. '05) Entered the allergy category with Mucinex(r) D (Oct. '05) Received 2nd patent covering Mucinex(r) and

Slide 7: Expanding Portfolio with Core Technology
$147.5 MM $49.8 MM Launched October 2005 Launch Expected in CY2006 Net Sales Trailing 12 Months as of 12/31/05 Expanding Portfolio with Core Technology Core technology: extended release guaifenesin Helps to thin phlegm (mucus) and bronchial secretions Useful when treating congestion: colds/allergies

Slide 8: Mucinex: Barriers to Entry
Mucinex(r): Barriers to Entry Additional Exclusivity (30 month stay upon competitive certification- par. IV) 2nd patent issued - 10/18/05 Both patents expire 2020 Rx Products withdrawn - Dec. 2003 Mucinex(r) NDA - (July 2002) Mucinex(r) DM NDA - (April 2004) Mucinex(r) D NDA - (June 2004) Drives con

Slide 9: Repeat Success with Mucinex Line Extensions
Competing Product Removal? Consumer Advertising Competing Product Removal? Repeat Success with Mucinex(r) Line Extensions Consumer Advertising November 2004 Competing Products Removed November 2003 Launched July 2002 Approved July 2002 $125 MM Rx market $39 MM Rx market Consumer Advertising November

Slide 10: Leading In-Season Brand
Leading In-Season Brand Source: IRI, Brand Ranking Report for the 4-week period ending 12/25/05 in the c/c/a/s category Peak Season Ranking: December '05 $9.9 $9.8 $8.3 $7.7 $7.5 $6.4 $5.6 $5.1 $5.0 $7.6 $8.6 $11.1 $18.2 $7.1 $11.9 $0.0 $2.0 $4.0 $6.0 $8.0 $10.0 $12.0 $14.0 $16.0 Sudafed Tylenol Col

Slide 11: Mucinex: Sales Velocity Outpaces Competition
Mucinex(r): Sales Velocity Outpaces Competition BRAND ($000s) # SKUs $ SKUs TOTAL NYQUIL $24,173 45 $537 TOTAL TYLENOL $23,696 103 $230 TOTAL ROBITUSSIN $23,391 58 $403 TOTAL MUCINEX(r) $20,324 6 $3,387 TOTAL SUDAFED $16,822 47 $358 TOTAL CLARITIN $16,839 29 $581 TOTAL BENADRYL $11,498 53 $217 TOTAL

Slide 12: Mucinex: Key Sales Driver in Drug
Mucinex(r): Key Sales Driver in Drug Source: IRI 52-week period ending 12/25/05, c/c/a/s category. (1) Higher ranking SKUs are 6 cigarettes, 3 beverages, 1 camera and 1 OTC product. SE 20's # 2 # 12 (1) SE 40's # 5 # 16 DM 20's # 7 DM 40's # 10 Top 500 UPC Dollar Ranking at Drug Outlets All OTC SKUs

Slide 13: Mucinex Unit Volume Reaches All-Time High
Mucinex(r) Unit Volume Reaches All-Time High Retail Consumption - Total Brand (20 ct equiv.) Source: Industry data week ending 1/15/06 04/05 Season 05/06 Season Peak season consumption more than doubled Surpassed last year's peak level by almost 200M units Consumption still growing post season peak

Slide 14: Mucinex Distribution: Strong in All Channels
Source: IRI - All commodity volume Mucinex(r) Distribution: Strong in All Channels Drug Food All Outlets +.2pts +22.5pts +8.7pts 99.3% 58.6% 84.5% 99.5% 81.1% 93.2% 0% 20% 40% 60% 80% 100% 12/26/2004 12/25/2005

Slide 15: Adams Enters the Allergy Category
Adams Enters the Allergy Category

Slide 16: Mucinex D Market Value
Thickened and excess mucus and respiratory congestion are expressed in both the upper and lower airways Mucinex(r) D Market Value $2.0 billion market $2.9 billion market* Source: IRI 52-week period ending 12/25/05, F/D/Mx.

Slide 17: Mucinex D Treats Excess Mucus
Mucinex(r) D Treats Excess Mucus Nasal congestion and sinus pressure sufferers are heavy users most likely to suffer throughout the year A significant complicating factor of allergic nasal congestion and sinus pressure is excess mucus Mucinex(r) D thins the excess mucus secretions in the sinus cavit

Slide 18: "Dance to the Mucus" television commercial
[At this point in the presentation, the "Dance to the Mucus" television commercial is shown.]

Slide 19: Adams' Long-Term Growth Strategy
Adams' Long-Term Growth Strategy Build Internal Pipeline by Extending Long-Acting Guaifenesin Platform to Other Respiratory Segments Aggressively In-License/Acquire New Specialty Pharma Respiratory Products Three - Pronged Strategy Drive Mucinex(r) Brand Awareness among Professionals and Consumers G

Slide 20: U.S. Development of Erdosteine
U.S. Development of Erdosteine In-licensed muco-regulator compound with a unique profile Published European studies showed significant improvements in: mucociliary clearance, mucus volume, flow characteristics and cough Approved in > 30 foreign markets; ~24 million patient exposures Phase II clinica

Slide 21: Financial Overview
Financial Overview aI

Slide 22: Strong Growth in Revenues
12-Months Ended 6-Months Ended Strong Growth in Revenues (in millions) 6/03 12/04 6/04 6/05 6/02 YoY Growth 78% CAGR '02-'05 126 % 12/05 $13.8 $14.0 $61.3 $160.2 $62.0 $110.3 $0.0 $20.0 $40.0 $60.0 $80.0 $100.0 $120.0 $140.0 $160.0 $180.0 2002 2003 2004 2005 2004 2005

Slide 23: Income Statement Overview
Income Statement Overview Includes $16.1 million tax benefit related to the future benefit of NOLs. Includes $2.5 million after-tax impact of the discretionary performance bonus. $110.3 $62.0 $160.2 $61.3 $14.0 Net Sales 79.6% 78.5% 80.6% 80.5% 62.6% Gross Margin $37.5 34% $15.1 24% $44.4 28% $19.7

Slide 24: Solid Financial Position
Solid Financial Position (in millions) Capitalization: As of June 30, 2005 As of Dec. 31 , 2005 Cash, Cash Equivalents and Short - - Term Investments $ 24.7 $ 153 .. 4 Redeemable Convertible Preferred Stock $ 316.5 $ - - Total Shareholders' Equity (273.6) 188.9 Total Capitalization $ 4 2.8 $ 188.9

Slide 25: Financial Outlook: Consumption/Production Analysis
If Consumption is: @ 8% share $64 million @ 9% share $72 million @10% share $80 million Financial Outlook: Consumption/Production Analysis Annual IRI Retail Sales (1) $2.9 billion IRI Retail Sales @ 3/31/06 (2) $800 million (1) IRI 52-weeks ended 12/25/05, F/D/Mx. (2) An assumption, for illustrative

Slide 26: Financial Outlook: Backorder Analysis
Financial Outlook: Backorder Analysis Backorder @ 12/31/05 $20 million Assumed orders @ 3/31/06 (1) $65 million Total orders to fill (1) $85 million (1) Provided for illustrative purposes only Assumed factory shipments (1) ($72 - 75) million Backorder @ 3/31/06 $10 -13 million

Slide 27: Financial Outlook: Gross Margin
Financial Outlook: Gross Margin Expect gross margin for remainder of FY 2006 to be consistent with second quarter gross margin (78%) Gross margin improvement related to Cardinal profit share arrangement in supply agreement Profit sharing percentage declines as the value of our gross margin increases

Slide 28: Future Growth Drivers
Future Growth Drivers Market Share Expansion Mucinex(r) D Allergy Mkt Revenues Children's Mucinex(r) Launch Humibid(r) Launch Exclusivity Decision on DM and D New Combo Products Erdosteine Acquisitions/ In-licensing Pricing Aggregate potential opportunity: $500 million + FY 2005 Net Revenue $160.2 M

Slide 29: Adams Respiratory Therapeutics
ADAMS RESPIRATORY THERAPEUTICS™ I\S

Slide 30: Guaifenesin Technology Patent Protection
Guaifenesin Technology Patent Protection Hours Cmax 0 6 12 FDA Tolerances/ +25% - -20% Level of Drug in Blood Cmin Adams Patent Broad tolerances in patent provide protection Maximum desired level in the blood Minimum desired level in the blood = IR guaifenesin, 400 mg tablet = Mucinex(r)

Slide 31: Patent Reexamination
Patent Reexamination Patent Reexamination Process Table Process Phase Time Required Patent Status Para IV Competitors Risks Pre - - appeal process · 1 st office action · Prosecution of re - - exam case Up to 36 mos ß 9 - - 12 months ß Up to 24 months Full force/effect Full force/effect Required Requ

Slide 32: Strong Intellectual Property
Strong Intellectual Property Proprietary platform technology developed by Adams Unique bi-layer tablet delivery system IP position protects unique pharmacokinetic profile Second patent issued October 18, 2005 Both patents expire 2020 Development platform applicable to product extensions Patent reexa

Slide 33: Planned Events for CY 2006
Planned Events for CY 2006 Initiate advertising campaign for Mucinex(r) D in advance of the spring allergy season (February 2006) Launch first maximum-strength Humibid(r) product (1H 2006) Introduce a line of Mucinex(r) products into the $300+ million pediatric segment (2H 2006) Continue investments
Source: SEC EDGAR · 8-K filed Feb 16, 2006
More decks from Adams Respiratory Therapeutics Inc
Q1 FY2008 Earnings Presentation12 slides · Nov 8, 2007
Q3 FY2007 Earnings Presentation21 slides · May 10, 2007
Technical Presentation (April 2007)25 slides · Apr 4, 2007
Investor Presentation (April 2007)10 slides · Apr 4, 2007
Investor Presentation (April 2007)60 slides · Apr 4, 2007
Merrill Lynch 18th Annual Global Pharmaceutical, Biotechnology and Medical Device Conferen (February 2007)21 slides · Feb 8, 2007